Shots:

• The P-II/III CAPELLA trial involves assessing lenacapavir (SC- every 6mos.) vs PBO in 36 participants in a ratio (2:1) with multi-drug resistant HIV-1 infection
• The study demonstrated virologic suppression @26wks.- viral load reduction from baseline of ≥ 0.5 log10 copies/mL for 14days functional monothx. period (88% vs 17)- low (150 mg/kg) and high dose (300 mg/kg) of GS-CA1 groups showed 86% and 96% infection risk reduction respectively and was well tolerated
• Lenacapavir is an investigational- long-acting HIV-1 capsid inhibitor in development for the treatment and prevention of HIV infection

 ­ Ref: Gilead | Image:Gilead